Type 3 deiodinase: Role in cancer growth, stemness, and metabolism

Frontiers in Endocrinology

Volumn 5, Issue DEC, 2014, Pages

  Ciavardelli, Domenico ^a,b   Bellomo, Maria ^a   Crescimanno, Caterina ^a   Vella, Veronica ^a,c  

^a KORE UNIVERSITY OF ENNA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cancer stem cells; Deiodinase; Stemness; Type 3 deiodinase; Warburg effect

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR; ESTROGEN; FIBROBLAST GROWTH FACTOR; HEAT SHOCK PROTEIN 40; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PROGESTERONE; PROTEIN P53; PYRUVATE KINASE; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; THYROID HORMONE; THYROXINE DEIODINASE; THYROXINE DEIODINASE 3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; WNT PROTEIN;

CANCER GROWTH; CANCER RECURRENCE; CARCINOGENESIS; CELL DIFFERENTIATION; CONCENTRATION (PARAMETERS); DNA TRANSCRIPTION; GENE; GENE OVEREXPRESSION; HORMONAL REGULATION; HUMAN; HYPOTHYROIDISM; HYPOXIA; INTRACELLULAR SIGNALING; METABOLISM; NEOPLASM; PHENOTYPE; PHYSICAL DEVELOPMENT; PROTEIN DEGRADATION; SHORT SURVEY;

EID: 84920118958     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00215     Document Type: Short Survey

References (77)

1. Yen PM, Ando S, Feng X, Liu Y, Maruvada P, Xia X. Thyroid hormone action at the cellular, genomic and target gene levels. Mol Cell Endocrinol (2006) 246(1-2):121-7. doi: 10.1016/j.mce.2005.11.030
2. Fisher DA. Clinical review 19: management of congenital hypothyroidism. J Clin Endocrinol Metab (1991) 72(3):523-9. doi:10.1210/jcem-72-3-523
3. Dentice M, Marsili A, Zavacki A, Larsen PR, Salvatore D. The deiodinases and the control of intracellular thyroid hormone signaling during cellular differentiation. Biochim Biophys Acta (2013) 1830(7):3937-45. doi:10.1016/j.bbagen.2012.05.007
4. Gereben B, Zeold A, Dentice M, Salvatore D, Bianco AC. Activation and inactivation of thyroid hormone by deiodinases: local action with general consequences. Cell Mol Life Sci (2008) 65(4):570-90. doi:10.1007/s00018-007-7396-0
5. Baqui M, Botero D, Gereben B, Curcio C, Harney JW, Salvatore D, et al. Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes. J Biol Chem (2003) 278(2):1206-11. doi:10.1074/jbc. M210266200
6. Bates JM, St Germain DL, Galton VA. Expression profiles of the three iodothyronine deiodinases, D1, D2, and D3, in the developing rat. Endocrinology (1999) 140(2):844-51. doi:10.1210/en.140.2.844
7. Hernandez A, Martinez ME, Fiering S, Galton VA, St Germain D. Type 3 deiodinase is critical for the maturation and function of the thyroid axis. J Clin Invest (2006) 116(2):476-84. doi:10.1172/JCI26240
8. Dussault JH, Coulombe P, Walker P. Effects of neonatal hyperthyroidism on the development of the hypothalamic-pituitary-thyroid axis in the rat. Endocrinology (1982) 110(3):1037-42. doi:10.1210/endo-110-3-1037
9. Kempers MJ, van Tijn DA, van Trotsenburg AS, de Vijlder JJ, Wiedijk BM, Vulsma T. Central congenital hypothyroidism due to gestational hyperthyroidism: detection where prevention failed. J Clin Endocrinol Metab (2003) 88(12):5851-7. doi:10.1210/jc.2003-030665
10. Casula S, Bianco AC. Thyroid hormone deiodinases and cancer. Front Endocrin (2012) 3:74. doi:10.3389/fendo.2012.00074
11. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev (2008) 29(7):898-938. doi:10.1210/er.2008-0019
12. Huang SA, Bianco AC. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat Clin Pract Endocrinol Metab (2008) 4(3):148-55. doi:10.1038/ncpendmet0727
13. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HP, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med (2000) 343(3):185-9. doi:10.1056/NEJM200007203430305
14. Kester MH, Kuiper GG, Versteeg R, Visser TJ. Regulation of type III iodothyronine deiodinase expression in human cell lines. Endocrinology (2006) 147(12):5845-54. doi:10.1210/en.2006-0590
15. Dentice M, Ambrosio R, Salvatore D. Role of type 3 deiodinase in cancer. Expert Opin Ther Targets (2009) 13(11):1363-73. doi:10.1517/14728220903339122
16. Dentice M, Luongo C, Ambrosio R, Sibilio A, Casillo A, Iaccarino A, et al. Beta-Catenin regulates deiodinase levels and thyroid hormone signaling in colon cancer cells. Gastroenterology (2012) 143(4):1037-47. doi:10.1053/j.gastro.2012.06.042
17. Howard D, La Rosa FG, Huang S, Salvatore D, Mulcahey M, Sang-Lee J, et al. Consumptive hypothyroidism resulting from hepatic vascular tumors in an athyreotic adult. J Clin Endocrinol Metab (2011) 96(7):1966-70. doi:10.1210/jc.2010-2104
18. Ruppe MD, Huang SA, Jan de Beur SM. Consumptive hypothyroidism caused by paraneoplastic production of type 3 iodothyronine deiodinase. Thyroid (2005) 15(12):1369-72. doi:10.1089/thy.2005.15.1369
19. Romitti M, Wajner SM, Zennig N, Goemann IM, Bueno AL, Meyer EL, et al. Increased type 3 deiodinase expression in papillary thyroid carcinoma. Thyroid (2012) 22(9):897-904. doi:10.1089/thy.2012.0031
20. Malaguarnera R, Vella V, Pandini G, Sanfilippo M, Pezzino V, Vigneri R, et al. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation. Mol Cancer Res (2008) 6(1):64-77. doi:10.1158/1541-7786.MCR-07-0005
21. Malaguarnera R, Vella V, Vigneri R, Frasca F. p53 family proteins in thyroid cancer. Endocr Relat Cancer (2007) 14(1):43-60. doi:10.1677/erc.1.01223
22. Malaguarnera R, Mandarino A, Mazzon E, Vella V, Gangemi P, Vancheri C, et al. The p53-homologue p63 may promote thyroid cancer progression. Endocr Relat Cancer (2005) 12(4):953-71. doi:10.1677/erc.1.00968
23. Vella V, Puppin C, Damante G, Vigneri R, Sanfilippo M, Vigneri P, et al. DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells. Int J Cancer (2009) 124(11):2539-48. doi:10.1002/ijc.24221
24. Messina RL, Sanfilippo M, Vella V, Pandini G, Vigneri P, Nicolosi ML, et al. Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. Int J Cancer (2012) 130(10):2259-70. doi:10.1002/ijc.26228
25. Hernandez A, Obregon MJ. Presence of growth factors-induced type III iodothyronine 5-deiodinase in cultured rat brown adipocytes. Endocrinology (1995) 136(10):4543-50. doi:10.1210/en.136.10.4543
26. Courtin F, Liva P, Gavaret JM, Toru-Delbauffe D, Pierre M. Induction of 5-deiodinase activity in astroglial cells by 12-O-tetradecanoylphorbol 13-acetate and fibroblast growth factors. J Neurochem (1991) 56(4):1107-13. doi:10.1111/j.1471-4159.1991.tb11399.x
27. Pallud S, Ramauge M, Gavaret JM, Lennon AM, Munsch N, St Germain DL, et al. Regulation of type 3 iodothyronine deiodinase expression in cultured rat astrocytes: role of the Erk cascade. Endocrinology (1999) 140(6):2917-23. doi:10.1210/endo.140.6.6834
28. Dentice M, Luongo C, Huang S, Ambrosio R, Elefante A, Mirebeau-Prunier D, et al. Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes. Proc Natl Acad Sci U S A (2007) 104(36):14466-71. doi:10.1073/pnas.0706754104
29. Huang SA. Physiology and pathophysiology of type 3 deiodinase in humans. Thyroid (2005) 15(8):875-81. doi:10.1089/thy.2005.15.875
30. Luongo C, Ambrosio R, Salzano S, Dlugosz AA, Missero C, Dentice M. The sonic hedgehog-induced type 3 deiodinase facilitates tumorigenesis of basal cell carcinoma by reducing Gli2 inactivation. Endocrinology (2014) 155(6):2077-88. doi:10.1210/en.2013-2108
31. Simonides WS, Mulcahey MA, Redout EM, Muller A, Zuidwijk MJ, Visser TJ, et al. Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. J Clin Invest (2008) 118(3):975-83. doi:10.1172/JCI32824
32. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev (2001) 15(23):3059-87. doi:10.1101/gad.938601
33. Strutt H, Thomas C, Nakano Y, Stark D, Neave B, Taylor AM, et al. Mutations in the sterol-sensing domain of patched suggest a role for vesicular trafficking in smoothened regulation. Curr Biol (2001) 11(8):608-13. doi:10.1016/S0960-9822(01)00179-8
34. Rahnama F, Shimokawa T, Lauth M, Finta C, Kogerman P, Teglund S, et al. Inhibition of GLI1 gene activation by patched1. Biochem J (2006) 394(Pt 1):19-26. doi:10.1042/BJ20050941
35. Bhardwaj G, Murdoch B, Wu D, Baker DP, Williams KP, Chadwick K, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol (2001) 2(2):172-80. doi:10.1038/84282
36. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 66(12):6063-71. doi:10.1158/0008-5472.CAN-06-0054
37. Ahn S, Joyner AL. In vivo analysis of quiescent adult neural stem cells responding to Sonic hedgehog. Nature (2005) 437(7060):894-7. doi:10.1038/nature03994
38. Ruiz I, Altaba A, Sanchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer (2002) 2(5):361-72. doi:10.1038/nrc796
39. Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature (2001) 411(6835):349-54. doi:10.1038/35077219
40. Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating smoothened mutations in sporadic basal-cell carcinoma. Nature (1998) 391(6662):90-2. doi:10.1038/34201
41. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science (1997) 277(5329):1109-13. doi:10.1126/science.277.5329.1109
42. Dentice M. Hedgehog-mediated regulation of thyroid hormone action through iodothyronine deiodinases. Expert Opin Ther Targets (2011) 15(4):493-504. doi:10.1517/14728222.2011.553607
43. Huntzicker EG, Estay IS, Zhen H, Lokteva LA, Jackson PK, Oro AE. Dual degradation signals control Gli protein stability and tumor formation. Genes Dev (2006) 20(3):276-81. doi:10.1101/gad.1380906
44. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell (2009) 17(1):9-26. doi:10.1016/j.devcel.2009.06.016
45. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev (1997) 11(24):3286-305. doi:10.1101/gad.11.24.3286
46. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer (2008) 8(5):387-98. doi:10.1038/nrc2389
47. Shi YB, Wong J, Puzianowska-Kuznicka M, Stolow MA. Tadpole competence and tissue-specific temporal regulation of amphibian metamorphosis: roles of thyroid hormone and its receptors. Bioessays (1996) 18(5):391-9. doi:10.1002/bies.950180509
48. Sirakov M, Plateroti M. The thyroid hormones and their nuclear receptors in the gut: from developmental biology to cancer. Biochim Biophys Acta (2011) 1812(8):938-46. doi:10.1016/j.bbadis.2010.12.020
49. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med (2000) 342(18):1350-8. doi:10.1056/NEJM200005043421807
50. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J (2000) 19(8):1745-54. doi:10.1093/emboj/19.8.1745
51. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature (2003) 425(6958):577-84. doi:10.1038/nature02006
52. Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGF-beta signal transduction. J Cell Sci (2001) 114(Pt 24):4359-69.
53. Huang SA, Dorfman DM, Genest DR, Salvatore D, Larsen PR. Type 3 iodothyronine deiodinase is highly expressed in the human uteroplacental unit and in fetal epithelium. J Clin Endocrinol Metab (2003) 88(3):1384-8. doi:10.1210/jc.2002-021291
54. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab (2003) 88(7):3202-11. doi:10.1210/jc.2002-022013
55. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist (2004) 9(Suppl 5):10-7. doi:10.1634/theoncologist.9-90005-10
56. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist (2004) 9(Suppl 5):4-9. doi:10.1634/theoncologist.9-90005-4
57. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell (2007) 129(3):465-72. doi:10.1016/j.cell.2007.04.019
58. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 15(6):501-13. doi:10.1016/j.ccr.2009.03.018
59. Wang Y, Liu Y, Malek SN, Zheng P. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell (2011) 8(4):399-411. doi:10.1016/j.stem.2011.02.006
60. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324(5930):1029-33. doi:10.1126/science.1160809
61. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis (2013) 4:e532. doi:10.1038/cddis.2013.60
62. Ciavardelli D, Rossi C, Barcaroli D, Volpe S, Consalvo A, Zucchelli M, et al. Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment. Cell Death Dis (2014) 5:e1336.
63. Zhou Y, Shingu T, Feng L, Chen Z, Ogasawara M, Keating MJ, et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem (2011) 286(37):32843-53.
64. Dong C, Yuan T, Wu Y, Wang Y, Fan TW, Miriyala S, et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell (2013) 23(3):316-31.
65. Morfouace M, Lalier L, Bahut M, Bonnamain V, Naveilhan P, Guette C, et al. Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications. J Biol Chem (2012) 287(40):33664-74. doi:10.1074/jbc. M111.320028
66. Menendez JA, Joven J, CufiS, Corominas-Faja B, Oliveras-Ferraros C, Cuyas E, et al. The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle (2013) 12(8):1166-79. doi:10.4161/cc.24479
67. Pecqueur C, Oliver L, Oizel K, Lalier L, Vallette FM. Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int J Cell Biol (2013) 2013:805975. doi:10.1155/2013/805975
68. Suhane S, Ramanujan VK. Thyroid hormone differentially modulates Warburg phenotype in breast cancer cells. Biochem Biophys Res Commun (2011) 414(1):73-8. doi:10.1016/j.bbrc.2011.09.024
69. Kato H, Fukuda T, Parkison C, McPhie P, Cheng SY. Cytosolic thyroid hormone-binding protein is a monomer of pyruvate kinase. Proc Natl Acad Sci U S A (1989) 86(20):7861-5. doi:10.1073/pnas.86.20.7861
70. Ashizawa K, McPhie P, Lin KH, Cheng SY. An in vitro novel mechanism of regulating the activity of pyruvate kinase M2 by thyroid hormone and fructose 1, 6-bisphosphate. Biochemistry (1991) 30(29):7105-11. doi:10.1021/bi00243a010
71. Jo S, Kallo I, Bardoczi Z, Arrojo e Drigo R, Zeold A, Liposits Z, et al. Neuronal hypoxia induces Hsp40-mediated nuclear import of type 3 deiodinase as an adaptive mechanism to reduce cellular metabolism. J Neurosci (2012) 32(25):8491-500. doi:10.1523/JNEUROSCI.6514-11.2012
72. Sterrenberg JN, Blatch GL, Edkins AL. Human DNAJ in cancer and stem cells. Cancer Lett (2011) 312(2):129-42. doi:10.1016/j.canlet.2011.08.019
73. Huang L, Yu Z, Zhang T, Zhao X, Huang G. HSP40 interacts with pyruvate kinase M2 and regulates glycolysis and cell proliferation in tumor cells. PLoS One (2014) 9(3):e92949. doi:10.1371/journal.pone.0092949
74. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 356(3):217-26. doi:10.1056/NEJMoa063994
75. Bianco AC, Maia AL, da Silva WS, Christoffolete MA. Adaptive activation of thyroid hormone and energy expenditure. Biosci Rep (2005) 25(3-4):191-208. doi:10.1007/s10540-005-2885-6
76. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer (2011) 11(5):325-37. doi:10.1038/nrc3038
77. Paladini RD, Saleh J, Qian C, Xu GX, Rubin LL. Modulation of hair growth with small molecule agonists of the hedgehog signaling pathway. J Invest Dermatol (2005) 125(4):638-46.